Transformation of the Ukrainian pharmaceutical market – new opportunities and potential Pharmaceutical Industry Review, September No 4 (97) 2023
significantly and is 40% of the total sales volume of the MAT market for March 2023, which is 9% more than the previous year. Centralized procurement, namely procurement by international procurement agencies (UNFPA, UNDP, Crown Agents) and procurement by the Central Procurement Agency Medical Procurement of Ukraine, significantly increased its market share – up to 16% by MAT in March 2023 compared to 11% for the same period last year. The influence on the market and the importance of the reimbursement the Affordable Medicines program have increased significantly. Taking fixed prices into account, the Affordable Medicines program showed greater growth in volume than in value terms, with its market share increasing from 3 to 6% in value (UAH) terms. Decentralized government procurement of hospitals increased the market share in terms of value (UAH) to 18% for MAT in March 2023 compared to 14% for the same period last year. The increase occurred in two directions: the first is the assortment of goods related to the war, which was purchased by certain medical institutions; the second – is regarding the internally displaced population (IDP) (this assortment was directed by the flow of IDP). The total volume of the drug market for the entire war year according to MAT in March 2023 was UAH 46 billion or USD 1.2 billion. The share of the category of drugs decreased mainly in the retail segment (-37% in kind and -28% in value (UAH) dimension) than in public procurement (-26 and -21%, respectively). This led to an increase in the state's overall market share to 33% for MAT in March 2023 (vs. 27% for MAT in March 2022), including the Affordable Medicines reimbursement program. It is important that despite the difficult situation due to the war, the state has even increased funding
10 BACK TO CONTENTS
and already covers a third of the entire drug market. The share of reimbursement due to the expansion of the Affordable Medicines program in such categories as diabetes (insulin), mental and behavioral disorders, and Parkinson's disease also increased significantly. The biggest negative impact on the market was the effect of a decrease in natural volume; also slightly more products disappeared from the market than
new ones were launched (-5% vs. +4%). Indian, Russian, and Belarusian companies, as well as small manufacturers with niche products, left the market. The price effect had a positive effect on the market (+14%), but was lower than the rate of inflation (27% per year)4
Import and local production Ukraine has always been a traditionally powerful local manufacturer of medicines. Since January 20115
.
, our country
www.promoboz.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
